ProCE Banner Series

Comprehensive Patient-Centric Care in HR+/HER2- MBC: Meeting the Full Spectrum of Patient Needs With Comorbidities and Related Factors

This 1.0-hour interactive live webinar will provide expert perspectives on optimal approaches to the management of patients with HR+/HER2- MBC with preexisting  comorbidities, including discussions of ways to minimize polypharmacy and drug–drug interactions.

  ACPE
Who Should Attend

This activity is intended for pharmacists, and other healthcare professionals involved in caring for patients with mBC.

All Events

Comprehensive Patient-Centric Care in HR+/HER2- MBC: Meeting the Full Spectrum of Patient Needs With Comorbidities and Related Factors

Upcoming Events

April

10

2025

1:00 PM - 2:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners' knowledge, competence, and performance in improving the comprehensive care of patients with HR+/HER2- mBC and existing comorbidities.

Target Audience
This activity is intended for pharmacists, and other healthcare professionals involved in caring for patients with mBC. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Describe common comorbidities and related factors in patients with HR+/HER2- mBC, including cardiovascular disease, polypharmacy, and poor performance status.
  • Select individualized treatment for patients with HR+/HER2- mBC, considering efficacy and safety data (RCT/RWE), treatment guidelines, and health status.
  • Implement effective multidisciplinary team processes to mitigate and monitor potential drug-drug interactions in patients with comorbid conditions.
  • Plan communication strategies, utilizing shared decision-making to optimize patient-physician trust and understand patient goals when selecting mBC treatment.
  • Evaluate available RWE for CDK4/6 inhibitors in patients with comorbid conditions and underrepresented subgroups in RCTs, such as geriatric patients.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-081-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC., in partnership with Practicing Clinicians Exchange (PCE) and ProCE, LLC.

Supported by an educational grant from Pfizer Inc.